Respiratory Syncytial Virus (RSV) in Infants and Children

Adam Welch, PharmD, MBA, FAPhA, leads a discussion surrounding payer considerations for RSV vaccinations in children.

Medical experts discuss current obstacles facing ideal respiratory syncytial virus (RSV) treatment strategies in children.

Long-term effects of pediatric RSV diagnosis are explored.

The panel highlights the current standards of care and strategies for treating children with RSV.

Revolutionary advancements in monoclonal antibodies are considered for prevention of RSV.

Preemptive treatment strategies for pediatric RSV are discussed by key opinion leaders.

RSV diagnosis can lead to an array of financial complications.

In their closing thoughts the panelists discuss reimbursement-related considerations surrounding mAbs.